Procaps Group S.A. (NASDAQ:PROC – Get Rating) rose 11.9% during trading on Friday . The stock traded as high as $5.00 and last traded at $5.00. Approximately 432 shares traded hands during mid-day trading, a decline of 98% from the average daily volume of 23,069 shares. The stock had previously closed at $4.47.
Procaps Group Stock Up 6.0 %
The company's 50 day moving average price is $6.23 and its 200 day moving average price is $7.16.
Get
Procaps Group alerts:
Procaps Group (NASDAQ:PROC – Get Rating) last issued its earnings results on Monday, November 14th. The company reported $0.22 earnings per share for the quarter, beating the consensus estimate of $0.13 by $0.09. The firm had revenue of $110.40 million for the quarter, compared to analysts' expectations of $123.90 million. Procaps Group had a net margin of 13.82% and a negative return on equity of 243.60%. As a group, sell-side analysts expect that Procaps Group S.A. will post 0.12 EPS for the current year.
Institutional Trading of Procaps Group
Hedge funds have recently added to or reduced their stakes in the company. State Street Corp acquired a new stake in Procaps Group in the third quarter valued at approximately $89,000. Citadel Advisors LLC acquired a new stake in Procaps Group in the second quarter valued at approximately $263,000. Finally, Millennium Management LLC raised its holdings in Procaps Group by 15.9% in the second quarter. Millennium Management LLC now owns 101,430 shares of the company's stock valued at $945,000 after acquiring an additional 13,908 shares in the last quarter. Institutional investors and hedge funds own 0.95% of the company's stock.
About Procaps Group
(Get Rating)
Procaps Group SA develops, produces, and markets pharmaceutical solutions worldwide. The company formulates, manufactures, and markets branded prescription drugs in various therapeutic areas, including feminine care products, pain relief, skin care, digestive health, growth and development, cardiology, vision care, central nervous system, and respiratory.
See Also
- Get a free copy of the StockNews.com research report on Procaps Group (PROC)
- MarketBeat: Week in Review 01/02-01/06
- Why is the CrowdStrike Stock Price Struggling?
- Four Undervalued Healthcare Stocks for 2023
- WWE Stock: Vince McMahon Wants Back In The Show
- NVIDIA Is Bottoming But Don't Buy It Just Yet
Receive News & Ratings for Procaps Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Procaps Group and related companies with MarketBeat.com's FREE daily email newsletter.
